Skip to main content

Table 2 Associations between pathway alterations

From: Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer

  PTEN mut PTEN wt n p HER2+ HER2- n p EGFR+ EGFR- n p PIK3CA mut PIK3CA wt n p INPP4B low INPP4B high n p
PTEN IHC- 3 20 103 0.010 2 23 107 0.117 14 11 107 <0.0001 1 24 107 0.012 6 11 85 0.111
PTEN IHC+ 1 79    18 64    12 70    23 59    12 56   
PTEN abrogation      2 24 107 0.098 14 12 107 <0.0001 2 24 107 0.072 6 12 85 0.155
PTEN normal      18 63    12 69    22 59    12 55   
HER2+          8 14 110 0.150 6 17 113 0.871 3 15 91 0.624
HER2-          19 69    22 68    16 57   
EGFR+              5 22 112 0.436 8 12 90 0.019
EGFR-              22 63    11 59   
PIK3CA mut                  4 24 94 0.281
PIK3CA wt                  16 50   
  1. Footnote: Significant p-values are indicated by bolding
  2. Abbreviations: mut mutant, wt wild-type